Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

Two infusions of natalizumab (300 mg or 3 mg/kg) vs placebo

Failure to induce clinical response (Panaccione 2010) CDAI ‐ (≥100 point reduction) · Patients with active Crohn's disease

Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in failure to induce clinical response at 6 weeks compared with placebo (low certainty).

1 finding from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.66 [0.35, 1.25]
2 studies · 1034 participants
Low

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Failure to induce clinical response at end of study · Participants with active Crohn's disease despite current treatment with infliximab

The review found no eligible studies for this question.

1 finding from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found